Oncology pharmaceutical tech company seeks investors for further growth

Company history/background

This successful Pharma-Tech company (NL-2023) is developing a range of products for the treatment of hard-to-fight tumors: more effective, fewer side effects, and affordable. Clinical experts indicate that this could well become a 'game changer with impact' in the market for targeted oncology medicines (US$ 80 billion in 2023 with an annual growth of 6-7%).

In addition to a better product with fewer side effects and an attractive return for investors, the founders and first-hour investors are also explicitly committed to keeping cancer care affordable and available to everyone. And that is possible (see USPs)!

The team licensed a technology platform (worldwide, exclusively) from a pharmaceutical institute with very favorable exit conditions. Within 2 years, the team developed the first products based on three very well-known cancer drugs.

These have now been successfully demonstrated for localized administration to combat aggressive solid tumors, such as pancreatic, liver, lung, and colon tumors, and specific forms of breast, bladder, and prostate cancer.

Company activities

The company is primarily raising a series of investments to develop multiple product-market combinations in-house and under its own management up to and including the second clinical phase. These are being tested in patients across multiple tumor diseases by clinical experts; the products are manufactured externally.

From the start of the second clinical phase (years 3-4), partnerships are envisaged with specialized pharmaceutical companies in oncology. These partners will then acquire the rights and take the final, expensive steps towards commercial approval (years 5-7).

Key Opinion Leaders from the Netherlands and the US are ready to start clinical trials in the Netherlands and the US as soon as the products are approved for the first clinical trials in patients in 2027.

Multiple Product-Market Combinations will become available because the widely used cancer drugs are used for multiple tumor diseases worldwide.

Unique selling points

The USPs are:

• More effective than conventional chemotherapy and targeted treatments
• Fewer/no side effects: outside the tumor mass, the delivered medication is immeasurable or barely measurable.
• Safe: all ingredients and medicines are approved for human pharmaceutical applications.
• Multiple PMCs: Every medicine that we include in the products is well-known and 'off-patent' in oncology and is used for multiple tumor diseases, and this is covered by our granted basic patents.
• Affordable and available, the platform uses existing pharmaceutical substances and medicines that are all off the patent.
• Affordable and flexible: making the products is a matter of pharmaceutical mixing and stirring. No chemical synthesis or expensive fermentation is involved, and it can also be prepared in hospital pharmacies.
• The patents on the composition of a wide range of products and all possible variants have now been approved in the US, China, and Japan, and the EU will most likely follow this year, 2025.

Other

EXIT: It is expected that the company will be acquired or go public during the phase 2 clinical trials. The founders and initial investors are aiming for an exit starting in year 6 or 7.

Investment need:

1. Internal Product and process development and scaling up: €186,000
2. External animal studies at qualified labs: €622,000
3. External pharmaceutical producer: budget for scaling up initial studies: €100,000
4. IP, consultants, admin, conferences and travel expenses: €350,000
5. Management team, 3 people: €236,000
6. Runway reserve: €150,000
7. To be picked up: €1,644,000